Back

Viking Therapeutics reports VK2735 maintained weight loss with monthly dosing

Verifying
  • Viking Therapeutics released clinical results for its obesity drug VK2735.
  • Once-monthly dosing maintained a substantial portion of weight loss after initial reduction.
  • The results prompted analysis involving South Korean companies with long-acting injectable technology.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Viking Therapeutics reports VK2735 maintained weight loss with monthly dosing - CoinPost Terminal